Hyku Biosciences raised a total of $64M in seed financing led by Chugai Venture Fund to advance its proprietary platform for developing precision medicines.

Nov 12, 2024•about 1 year ago

Amount Raised

$64 Million

Round Type

seed

LexingtonTherapeuticsBiotechnologyHealth Care

Investors

Eisai InnovationKb InvestmentThe Mark Foundation For Cancer ResearchDroia VenturesNovartis Venture FundRa Capital ManagementChugai Venture Fund

Description

Hyku Biosciences Inc. appointed John Gustofson to its Board of Directors alongside a significant investment from Chugai Venture Fund. This investment brings the company's total seed financing to $64M, supporting its efforts in developing innovative precision medicines.

Company Information

Company

Hyku Biosciences

Location

Lexington, Massachusetts, United States

About

Hyku is a biotechnology company based in the greater Boston area, utilizing its proprietary discovery platform to inhibit disease targets that are challenging to address with conventional approaches. Hyku’s drug discovery engine is based on its proprietary platform technologies, which identify histidine, tyrosine and lysine-based binding pockets and enable rational drug design for the development of covalent or non-covalent medicines. The platform pioneered by Hyku has the potential to fundamentally expand the scope of small molecule drug discovery, greatly increase the potential to modulate many target classes, and bring significant therapeutic benefits to patients via first-in-class and best-in-class medicines.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends